Company: GANX
Filing Date: 2025-11-28
Form Type: 8-K
Source: 0001104659-25-116947
Chunk: 0

Company: Gain Therapeutics, Inc.
Filing Date: 2025-11-28
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On November
28, 2025, Gain Therapeutics, Inc. (the “ Company”), filed a prospectus supplement (the “ Prospectus Supplement”)
with the U. S. Securities and Exchange Commission (the “ SEC”) in connection with the Company’s “at the market offering”
program for the offer and sale of up to $35,530,980.56 of the Company’s common stock, par value $0.0001 per share (the “ Common
Stock”), from time to time through Oppenheimer & Co. Inc. (“ Oppenheimer”), as sales agent, pursuant to the Company’s
existing Equity Distribution Agreement (the “ Distribution Agreement”), dated September 6, 2024. As of the date hereof, the
Company has sold an aggregate of $14,469,019.44 of Common Stock pursuant to the Distribution Agreement and the related prospectus supplement,
dated September 6, 2024 to the Company’s Registration Statement on Form S-3 (File No. 333-265061).

The offer
and sale of additional Common Stock by the Company under the Distribution Agreement will be made pursuant to the Prospectus Supplement,
dated November 28, 2025, and the accompanying base prospectus, dated November 26, 2025, contained therein, which together form a part
of the Company’s shelf registration statement on Form S-3 (File No. 333-287622), initially filed with the SEC on May 28, 2025 and
which became effective on November 26, 2025 (the “ Registration Statement”).

Lowenstein
Sandler LLP, counsel to the Company, has issued a legal opinion relating to the validity of the $35,530,980.56 of Common Stock that may
be offered and sold pursuant to the Distribution Agreement and related Prospectus Supplement. A copy of such legal opinion, including
the consent included therein, is attached as Exhibit 5.1 to this Current Report on Form 8-K.

This Current
Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Shares discussed herein, nor
shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or jurisdiction.

Item 9.01. Financial Statements and Exhibits.